Literature DB >> 34073585

Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin.

Giovanni Mauri1,2, Lorenzo Monfardini3, Andrea Garnero4,5, Maria Giulia Zampino6, Franco Orsi1, Paolo Della Vigna1, Guido Bonomo1, Gianluca Maria Varano1, Marco Busso4, Carlo Gazzera7, Paolo Fonio5,7, Andrea Veltri4,8, Marco Calandri4,8.   

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide and has a high rate of metastatic disease which is the main cause of CRC-related death. Oligometastatic disease is a clinical condition recently included in ESMO guidelines that can benefit from a more aggressive locoregional approach. This review focuses the attention on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic locoregional strategies drawn from the current literature and consensus conferences. The different percutaneous therapies (radiofrequency ablation, microwave ablation, irreversible electroporation) as well as trans-arterial approaches (chemoembolization and radioembolization) are discussed. Ablation margins, the choice of the imaging guidance as well as characteristics of the different ablation techniques and other technical aspects are analyzed. A specific attention is then paid to the increasing role of biomarkers (in particular molecular profiling) and their role in the selection of the proper treatment for the right patient. In conclusion, in this review an up-to-date state of the art of the application of locoregional treatments on CRLM is provided, highlighting both technical aspects and the role of biomarkers, two sides of the same coin.

Entities:  

Keywords:  chemotherapy; colorectal cancer; loco regional treatments; oligometastatic disease; surgery

Year:  2021        PMID: 34073585     DOI: 10.3390/cancers13112617

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  126 in total

1.  Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.

Authors:  Bertrand Janne d'Othée; Constantinos T Sofocleous; Nader Hanna; Robert J Lewandowski; Michael C Soulen; Jean-Nicolas Vauthey; Steven J Cohen; Alan P Venook; Matthew S Johnson; Andrew S Kennedy; Ravi Murthy; Jean-Francois Geschwind; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2012-02       Impact factor: 3.464

2.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

Review 3.  Biomarkers in colorectal liver metastases.

Authors:  S Yamashita; Y S Chun; S E Kopetz; J-N Vauthey
Journal:  Br J Surg       Date:  2018-03-26       Impact factor: 6.939

4.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

5.  Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.

Authors:  John B Ammori; Nancy E Kemeny; Yuman Fong; Andrea Cercek; Ronald P Dematteo; Peter J Allen; T Peter Kingham; Mithat Gonen; Philip B Paty; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2013-06-15       Impact factor: 5.344

6.  Hepatic artery infusion chemotherapy for metastatic colorectal cancer to the liver at the lahey clinic: comparison between two methods of treatment, surgical versus percutaneous catheter placement.

Authors:  Richard A Oberfield; Eric Sampson; Gerald J Heatley
Journal:  Am J Clin Oncol       Date:  2004-08       Impact factor: 2.339

7.  Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Authors:  Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman
Journal:  Clin Cancer Res       Date:  2014-08-19       Impact factor: 12.531

8.  Unusual tumour ablations: report of difficult and interesting cases.

Authors:  Giovanni Mauri; Luca Nicosia; Gianluca Maria Varano; Paul Shyn; Sergio Sartori; Paola Tombesi; Francesca Di Vece; Franco Orsi; Luigi Solbiati
Journal:  Ecancermedicalscience       Date:  2017-04-18

9.  Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis.

Authors:  Kathy P Willowson; Aimee R Hayes; David L H Chan; Michael Tapner; Elizabeth J Bernard; Richard Maher; Nick Pavlakis; Stephen J Clarke; Dale L Bailey
Journal:  EJNMMI Res       Date:  2017-05-23       Impact factor: 3.138

Review 10.  Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.

Authors:  Luai R Zarour; Sudarshan Anand; Kevin G Billingsley; William H Bisson; Andrea Cercek; Michael F Clarke; Lisa M Coussens; Charles E Gast; Cristina B Geltzeiler; Lissi Hansen; Katherine A Kelley; Charles D Lopez; Shushan R Rana; Rebecca Ruhl; V Liana Tsikitis; Gina M Vaccaro; Melissa H Wong; Skye C Mayo
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.